13 unchanged sentences
and Jefferies LLC.
−Removed: Transition and Consulting Agreement, dated June 30, 2020 by and between Corvus Pharmaceuticals, Inc.
−Removed: and Joseph Buggy
+Added: Phase I/IB Combination Study Agreement, dated October 5, 2015, by and between Corvus Pharmaceuticals, Inc.
+Added: and Genentech, Inc.
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).
7 unchanged sentences
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
−Removed: The cover page of Corvus Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, formatted in Inline XBRL (contained in Exhibit 101).
−Removed: Indicates management contract or compensatory plan
+Added: The cover page of Corvus Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, formatted in Inline XBRL (contained in Exhibit 101).
+Added: Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K.
+Added: Exhibit being refiled upon expiration of confidential treatment previously granted by the SEC.
The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Corvus Pharmaceuticals, Inc.
2 unchanged sentences
CORVUS PHARMACEUTICALS, INC.
−Removed: July 30, 2020
+Added: October 29, 2020
President, Chief Executive Officer and Director
(Principal Executive Officer)
−Removed: July 30, 2020
+Added: October 29, 2020
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.